New Discovery Is Potential Key To Obesity Treatment

December 02, 1998

Scientists say they have demonstrated, for the first time, how a newly discovered and purified protein regulates control of feeding behavior. The research, done at Amgen in Thousand Oaks, Calif., could lead to new strategies for treating obesity.

Details of this development are in the November 17 issue of the peer-reviewed journal Biochemistry, which is published by the American Chemical Society, the world's largest scientific society.

Obesity researchers have been increasingly interested in a brain system called the melanocortin pathway. "The evidence is really piling up that this pathway is likely to be important in the regulation of food intake by the brain," says Amgen scientist Kevin Stark, Ph.D. When the alpha-melanocyte stimulating hormone (alpha-MSH) binds to melanocortin-3 or melanocortin-4 receptors in the brain, the pathway is activated and signals are sent to reduce food intake.

Scientists at Amgen had previously found a gene, called Agrp, that they suspected to be an important regulator of the melanocortin pathway. Now they have shown that the product of that gene, a protein they call AGRP, blocks the binding of alpha-MSH. The researchers believe the likely result is increased food consumption. While this might be desirable sometimes, too much AGRP may be a problem.

Previous work by the Amgen scientists also has shown that levels of AGRP are about ten-fold higher in mice which are genetically obese, or have fasted. While no studies have been reported yet on the levels of AGRP in humans, previous research by other groups shows two genes that interact with AGRP in this pathway (those for alpha-MSH and the melanocortin-4 receptor) are mutated in some obese humans.

A number of other genes such as leptin appear to be related to obesity. However, now that the mechanism of action of purified AGRP is known, Amgen researchers think it reveals another potential point of attack for an anti-obesity drug. The challenge will be designing a drug that prevents AGRP from binding to receptors within the melanocortin system.
-end-
A nonprofit organization with a membership of more than 155,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.



American Chemical Society

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.